Latest Anticoagulants Stories

(Ivanhoe Newswire)-- Patients who are receiving chemotherapy for cancer are at risk for venous thromboembolism.  Now, researchers show how a new treatment may help. In a double blind study the effectiveness and safety of ultra-low-molecular-weight heparin semuloparin was tested in the prevention of venous thromboembolism in patients with metastatic or locally advanced solid tumors who are just starting to receive chemotherapy. The results showed that venous thromboemeolism occurred in...

For decades, the blood thinner heparin has been used to prevent and treat blood clots. Could it be just as effective in treating cancer? In an editorial published today in the New England Journal of Medicine, researchers from McMaster University and the University at Buffalo suggest conclusive answers to key questions on the benefits of low molecular weight heparin (LMWH) for cancer patients remain elusive - despite promising results from large studies. Co-authors of the editorial are...

The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood clots, use of LMWH is low compared to...

DENVER, Feb. 14, 2012 /PRNewswire/ -- The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing...

MONTGOMERY, Ala., Feb. 13, 2012 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. today announced data assessing the effect of LIVALO® (pitavastatin) compared with Crestor® (rosuvastatin) on steady-state pharmacodynamics (PD) of warfarin by measuring international normalized ratio (INR) in healthy adult subjects.(1) The study, published in Current Medical Research & Opinion, showed INR during stable warfarin treatment did not change significantly when LIVALO was...

New evidence-based guidelines from the American College of Chest Physicians (ACCP) recommend considering individual patients' risk of thrombosis when deciding for or against the use of preventive therapies for deep vein thrombosis (DVT) and venous thromboembolism (VTE). Specifically, the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, published in the February issue of the journal CHEST, focus on...

Occasional erratic heart rhythms appear to cause about one-fifth of strokes for which a cause is not readily established, according to research presented at the American Stroke Association's International Stroke Conference 2012. About one-third of survivors leave the hospital with the cause of their stroke still undetermined. "Identifying and treating these patients for irregular rhythm could reduce the recurrence of stroke by 40 percent compared to reducing the risk by treating them...

For patients with a type of irregular heart beat called atrial fibrillation (AF), a new anti-clotting drug might be better at preventing clot-related strokes while minimizing the risk of causing a bleeding stroke. The research was presented at the American Stroke Association's International Stroke Conference 2012. The finding stems from a sub-analysis of data in a large, randomized clinical trial called ROCKET AF, conducted in 45 countries at 1,178 sites. ROCKET AF tested the new drug...

The anticoagulant dabigatran is associated with an increased risk of myocardial infarction (heart attack) or acute coronary syndrome in a broad spectrum of patients when tested against some other medicines, according to a study published Online First by the Archives of Internal Medicine, one of the JAMA/Archives journals. "Clinicians should consider the potential of these serious harmful cardiovascular effects with use of dabigatran," the study concludes. Dabigatran etexilate was...

RARITAN, N.J., Dec. 29, 2011 /PRNewswire/ -- Janssen Research & Development, LLC (JRD) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO(®) (rivaroxaban), an oral anticoagulant, to reduce the risk of (thrombotic) cardiovascular events in patients with Acute Coronary Syndrome (ACS). The filing is supported by data from the pivotal Phase 3 ATLAS ACS 2 TIMI 51...